IDEXX LABORATORIES INC /DE DEF 14A Filing

Ticker: IDXX · Form: DEF 14A · Filed: Mar 27, 2024 · CIK: 874716

Idexx Laboratories Inc /De DEF 14A Filing Summary
FieldDetail
CompanyIdexx Laboratories Inc /De (IDXX)
Form TypeDEF 14A
Filed DateMar 27, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$3.5 billion, $10, $45 billion, $3.7 B, $1.1 B
Sentimentneutral

Sentiment: neutral

Topics: DEF 14A, Proxy Statement, Executive Compensation, Corporate Governance, IDEXX LABORATORIES

TL;DR

<b>IDEXX LABORATORIES INC /DE filed its Definitive Proxy Statement for the fiscal year ended December 31, 2023.</b>

AI Summary

IDEXX LABORATORIES INC /DE (IDXX) filed a Proxy Statement (DEF 14A) with the SEC on March 27, 2024. Filing Type: DEF 14A (Definitive Proxy Statement). Reporting Period: Fiscal year ended December 31, 2023. Filed As Of Date: March 27, 2024. Company Name: IDEXX LABORATORIES INC /DE. Incorporated In: Delaware.

Why It Matters

For investors and stakeholders tracking IDEXX LABORATORIES INC /DE, this filing contains several important signals. This filing provides detailed information regarding the company's governance, executive compensation, and shareholder proposals for the past fiscal year. As a DEF 14A filing, it is crucial for investors to review the details on executive pay and board recommendations before the annual shareholder meeting.

Risk Assessment

Risk Level: low — IDEXX LABORATORIES INC /DE shows low risk based on this filing. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material financial information or significant operational changes.

Analyst Insight

Review the executive compensation details and any shareholder proposals to understand management's incentives and potential changes in corporate governance.

Key Numbers

  • 2023-12-31 — Fiscal Year End (Conformed Period of Report)
  • 2024-03-27 — Filing Date (Filed As Of Date)
  • DEF 14A — Form Type (Filing Values)
  • 000-19271 — SEC File Number (Filing Values)

Key Players & Entities

  • IDEXX LABORATORIES INC /DE (company) — Filer
  • 2023-12-31 (date) — Conformed Period of Report
  • 2024-03-27 (date) — Filed As Of Date
  • DE (jurisdiction) — State of Incorporation
  • 2835 (sic_code) — Standard Industrial Classification
  • 0000874716 (company_id) — Central Index Key
  • WESTBROOK (location) — Business Address City
  • ME (state) — Business Address State

FAQ

When did IDEXX LABORATORIES INC /DE file this DEF 14A?

IDEXX LABORATORIES INC /DE filed this Proxy Statement (DEF 14A) with the SEC on March 27, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by IDEXX LABORATORIES INC /DE (IDXX).

Where can I read the original DEF 14A filing from IDEXX LABORATORIES INC /DE?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by IDEXX LABORATORIES INC /DE.

What are the key takeaways from IDEXX LABORATORIES INC /DE's DEF 14A?

IDEXX LABORATORIES INC /DE filed this DEF 14A on March 27, 2024. Key takeaways: Filing Type: DEF 14A (Definitive Proxy Statement). Reporting Period: Fiscal year ended December 31, 2023. Filed As Of Date: March 27, 2024.

Is IDEXX LABORATORIES INC /DE a risky investment based on this filing?

Based on this DEF 14A, IDEXX LABORATORIES INC /DE presents a relatively low-risk profile. The filing is a routine DEF 14A, which is standard for public companies and does not contain new material financial information or significant operational changes.

What should investors do after reading IDEXX LABORATORIES INC /DE's DEF 14A?

Review the executive compensation details and any shareholder proposals to understand management's incentives and potential changes in corporate governance. The overall sentiment from this filing is neutral.

How does IDEXX LABORATORIES INC /DE compare to its industry peers?

IDEXX LABORATORIES INC /DE operates in the In Vitro & In Vivo Diagnostic Substances industry. This filing is a routine proxy statement.

Are there regulatory concerns for IDEXX LABORATORIES INC /DE?

The filing is a DEF 14A, which is a standard disclosure document required by the SEC for public companies.

Industry Context

IDEXX LABORATORIES INC /DE operates in the In Vitro & In Vivo Diagnostic Substances industry. This filing is a routine proxy statement.

Regulatory Implications

The filing is a DEF 14A, which is a standard disclosure document required by the SEC for public companies.

What Investors Should Do

  1. Analyze executive compensation packages and stock award details.
  2. Review any shareholder proposals and management's recommendations.
  3. Note the dates for the annual shareholder meeting and proxy voting deadlines.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a standard annual disclosure. Specific financial performance data for the reporting period will be found in other filings like the 10-K.

Filing Stats: 4,490 words · 18 min read · ~15 pages · Grade level 15.2 · Accepted 2024-03-27 16:00:36

Key Financial Figures

  • $3.5 billion — , IDEXX is an S&P 500 company with over $3.5 billion in annual revenue, approximately 11,000
  • $10 — in diluted earnings per share (EPS) of $10.06, representing 25% reported growth an
  • $45 billion — better serve and realize the estimated $45 billion total global addressable companion anim
  • $3.7 B — ting Profit Diluted Earnings Per Share $3.7 B $1.1 B $10.06 +9% over 2022 and +9%
  • $1.1 B — fit Diluted Earnings Per Share $3.7 B $1.1 B $10.06 +9% over 2022 and +9% organic
  • $10.06 — ted Earnings Per Share $3.7 B $1.1 B $10.06 +9% over 2022 and +9% organic revenue
  • $907 M — ng Cash Flow 4 Free Cash Flow 4 ROIC $907 M $773 M 47.5% +67% higher than 2022
  • $773 M — Flow 4 Free Cash Flow 4 ROIC $907 M $773 M 47.5% +67% higher than 2022 +96% hig
  • $2.1 B — d to Share Repurchases, 2019 - 2023 5 $2.1 B 6% $397 Capital allocated to share re
  • $397 — Repurchases, 2019 - 2023 5 $2.1 B 6% $397 Capital allocated to share repurchases
  • $80 million — 2. Includes ~280 bps benefit related to $80 million of discrete in-license of technology in
  • $16 million — te in-license of technology in 2022 and $16 million customer contract resolution in 2023.
  • $100 — ARY + + + * Assumes the investment of $100 on December 31, 2018 in IDEXX's common
  • $45 b — cs revenue opportunity is approximately $45 billion, with approximately two-thirds of

Filing Documents

Executive Compensation

Executive Compensation 71 Executive Officers 71 Compensation Discussion and Analysis 74 Executive Summary 75 Key Compensation Practices and Policies 80 How We Determine Compensation 82 Compensation Benchmarking and Peer Group 84 How We Paid Our NEOs in 20 23 86 How We Manage Risk and Governance 94 Compensation and Talent Committee Report 96

Executive Compensation Tables

Executive Compensation Tables 97 Pay Versus Performance 104 CEO Pay Ratio 109 Equity Compensation Plan Information 110 Stock Incentive Plans 110

Executive Compensation Recovery Policy (Clawback Policy)

Executive Compensation Recovery Policy (Clawback Policy) 112 Potential Payments Upon Termination or Change in Contro l 112 Proposal Four - Shareholder Proposal Regarding Simple Majority Vote 119 120 General Information About the 2024 Annual Meeting and Voting 121 This Proxy Statement and How Proxies Work 121 Who Can Vote 121 Notice of Internet Availability (Notice and Access) 121 How to Vote 122 Revoking a Proxy 122 Quorum 123 Votes Needed 123 Broker Non-Votes 123 Conduct of the 202 4 Annual Meeting 123 Pre-Meeting Forum and Submitting Questions 124 Virtual 202 4 Annual Meeting 124 Voting on Other Matters 124 Solicitation of Proxies 125 Householding of Annual Meeting Materials 125 Requirements for Submission of Proxy Proposals, Nomination of Directors and Other Business of Shareholders 126 Proposals Submitted Under Rule 14a-8 126 Proposals Submitted Outside of Rule 14a-8 126

Forward-Looking Statements

Forward-Looking Statements 128 Other Matters 129 Appendix A - Reconciliation of Non-GAAP Financial Measures 130 Proxy Summary Voting Roadmap Meeting Details Date and Time Monday, May 6, 2024, 4:30 p.m., Eastern Time Location Virtual meeting online via audio webcast at www. virtualshareholdermeeting.com/IDXX2024 Record Date The Company's Board of Directors (Board) has fixed the close of business on March 8, 2024 as the record date for the determination of shareholders entitled to notice of and to vote at the 2024 Annual Meeting. Ways to Vote By Telephone For registered holders: 1-800-690-6903 + For beneficial owners: 1-800-454-8683 + By Internet Before the meeting: www.proxyvote.com + During the meeting: www.virtualshareholder meeting.com/IDXX2024 + By Mail For registered holders: Request a paper proxy card by calling 1-800-579-1639 or send an email to sendmaterial@proxyvote.com . For beneficial owners: Mark, sign and date your voting instruction form and return it in the postage-paid envelope provided. + You will need the control number included in your Notice of Internet Availability, your proxy card or the voting instruction form that accompanies your proxy materials. Proposal Recommendations Proposal Board Vote Recommendation Page Number for Reference 1 Election of Directors FOR each nominee 18 2 Ratification of Appointment of Independent Registered Public Accounting Firm FOR 65 3 Advisory Vote to Approve Executive Compensation FOR 70 4 Shareholder Proposal Regarding Simple Majority Vote NONE 119 IDEXX 2024 PROXY STATEMENT 1 + + + PROXY SUMMARY 01 Election of Directors To elect Ms. Irene Chang Britt, Mr. Bruce L. Claflin, Dr. Asha S. Collins and Mr. Sam Samad as Class I Directors with a term expiring at the 2027 Annual Meeting. The Board of Directors recommends a vote "FOR" the four Director nominees up for election. Refer to page 18 for further information about our Director nominees. Board C

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.